Inhibition of Cell Proliferation, Vascular Endothelial Growth Factor and Tumor Growth by Albendazole

REFERENCES

• Folkman J. Angiogenesis: an organizing principle for drug discovery?. Nat Rev Drug Disco 2007; 6: 273–286
   PubMed Web of Science ®Google Scholar
• Ferrara N. VEGF as a therapeutic target in cancer. Oncology 2005; 69: 11–16
   PubMed Web of Science ®Google Scholar
• Longo R., Gasparini G. Challenges for patient selection with VEGF inhibitors. Cancer Chemother Pharmacol 2007; 60: 151–170
   PubMed Web of Science ®Google Scholar
• Bates D. O., Harper S. J. Regulation of vascular permeability by vascular endothelial growth factors. Vascul Pharmacol 2002; 39: 225–237
   PubMed Web of Science ®Google Scholar
• Roy H., Bhardwaj S., Yla-Herttuala S. Biology of vascular endothelial growth factors. FEBS Lett 2006; 580: 2879–2887
   PubMed Web of Science ®Google Scholar
• Shojaei F., Ferrara N. Antiangiogenic therapy for cancer: An update. Cancer J 2007; 13: 345–348
   PubMed Web of Science ®Google Scholar
• Boocock C. A., Charnock-Jones D. S., Sharkey A. M., McLaren J., Barker P. J., Wright K. A., Twentyman P. R., Smith S. K. Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Natl Cancer Inst 1995; 87: 506–516
   PubMed Web of Science ®Google Scholar
• Ferrara N., Kerbel R. S. Angiogenesis as a therapeutic target. Nature 2005; 438: 967–974
   PubMed Web of Science ®Google Scholar
• Brustmann H., Naude S. Vascular endothelial growth factor expression in serous ovarian carcinoma: Relationship with high mitotic activity and high FIGO stage. Gynecol. Oncol 2002; 84: 47–52
   PubMed Web of Science ®Google Scholar
• Mesiano S., Ferrara N., Jaffe R. B. Role of vascular endothelial growth factor in ovarian cancer: Inhibition of ascites formation by immunoneutralization. Am J Pathol 1998; 153: 1249–1256
   PubMed Web of Science ®Google Scholar
• Rad F. H., Le Buanec H., Paturance S., Larcier P., Genne P., Ryffel B., Bensussan A., Bizzini B., Gallo R. C., Zagury D., Uzan G. VEGF kinoid vaccine, a therapeutic approach against tumor angiogenesis and metastases. Proc Nat Acad Sci USA 2007; 104: 2837–2842
   PubMed Web of Science ®Google Scholar
• Ferrara N., Hillan K. J., Gerber H. P., Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nature Rev Drug Discovery 2004; 3: 391–400
   PubMed Web of Science ®Google Scholar
• Zhong H., Bowen J. P. Molecular design and clinical development of VEGFR kinase inhibitors. Curr Top Med Chem 2007; 7: 1379–1393
   PubMed Web of Science ®Google Scholar
• Homsi J., Daud A. I. Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors. Cancer Control 2007; 14: 285–294
   PubMedGoogle Scholar
• Karashima T., Inoue K., Fukata S., Iiyama T., Kurabayashi A., Kawada C., Shuin T. Blockade of the vascular endothelial growth factor-receptor 2 pathway inhibits the growth of human renal cell carcinoma, RBM1-IT4, in the kidney but not in the bone of nude mice. Int J Onco 2007; 30: 937–945
   PubMed Web of Science ®Google Scholar
• Horton J. Albendazole: A review of anthelmintic efficacy and safety in humans. Parasitology 2000; 121(Suppl)S113–132
   PubMedGoogle Scholar
• Pourgholami M. H., Woon L., Almajd R., Akhter J., Bowery P., Morris D. L. In vitro and in vivo suppression of growth of hepatocellular carcinoma cells by albendazole. Cancer Lett 2001; 165: 43–49
   PubMed Web of Science ®Google Scholar
• Pourgholami M. H., Akhter J., Wang L., Lu Y., Morris D. L. Antitumor activity of albendazole against the human colorectal cancer cell line HT-29: In vitro and in a xenograft model of peritoneal carcinomatosis. Cancer Chemother & Pharmacol 2005; 55: 425–432
   PubMed Web of Science ®Google Scholar
• Cachoux F., Isarno T., Wartmann M., Altmann K. H. Total synthesis and biological assessment of benzimidazole-based analogues of epothilone A: Ambivalent effects on cancer cell growth inhibition. Chembiochem 2006; 7: 54–57
   PubMed Web of Science ®Google Scholar
• Potashman M. H., Bready J., Coxon A., DeMelfi T. M., Jr., DiPietro L., Doerr N., Elbaum D., Estrada J., Gallant P., Germain J., Gu Y., Harmange J. C., Kaufman S. A., Kendall R., Kim J. L., Kumar G. N., Long A. M., Neervannan S., Patel V. F., Polverino A., Rose P., Plas S., Whittington D., Zanon R., Zhao H. Design, synthesis, and evaluation of orally active benzimidazoles and benzoxazoles as vascular endothelial growth factor-2 receptor tyrosine kinase inhibitors. J Med. Chem 2007; 50: 4351–4373
   PubMed Web of Science ®Google Scholar
• Pourgholami M. H., Cai Y. Z., Lu Y., Wang L., Morris D. L. Albendazole: a potent inhibitor of vascular endothelial growth factor and malignant ascites formation in OVCAR-3 tumor-bearing nude mice. Clin. Cancer Res. 2006; 12: 1928–1935
   PubMed Web of Science ®Google Scholar
• Byrne A. T., Ross L., Holash J., Nakanishi M., Hu L., Hofmann J. I., Yancopoulos G. D., Jaffe R. B. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res 2003; 9: 5721–5728
   PubMed Web of Science ®Google Scholar
• Kowanetz M., Ferrara N. Vascular endothelial growth factor signaling pathways: Therapeutic perspective. Clin. Cancer Res. 2006; 12: 5018–5022
   PubMed Web of Science ®Google Scholar
• Hu L., Zaloudek C., Mills G. B., Gray J., Jaffe R. B. In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002). Clin Cancer Res 2000; 6: 880–886
   PubMed Web of Science ®Google Scholar
• Xu L., Yoneda J., Herrera C., Wood J., Killion J. J., Fidler I. J. Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Int J Oncol 2000; 16: 445–454
   PubMed Web of Science ®Google Scholar
• Holash J., Davis S., Papadopoulos N., Croll S. D., Ho L., Russell M., Boland P., Leidich R., Hylton D., Burova E., Ioffe E., Huang T., Radziejewski C., Bailey K., Fandl J. P., Daly T., Wiegand S. J., Yancopoulos G. D., Rudge J. S. VEGF-Trap:A VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A 2002; 99: 11393–11398
   PubMed Web of Science ®Google Scholar
• Liang W. C., Wu X., Peale F. V., Lee C. V., Meng Y. G., Gutierrez J., Fu L., Malik A. K., Gerber H. P., Ferrara N., Fuh G. Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J Biol Chem 2006; 281: 951–961
   PubMed Web of Science ®Google Scholar
• Carmeliet P., Jain R. K. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249–257
   PubMed Web of Science ®Google Scholar
• Fukumura D., Xavier R., Sugiura T., Chen Y., Park E. C., Lu N., Selig M., Nielsen G., Taksir T., Jain R. K., Seed B. Tumor induction of VEGF promoter activity in stromal cells. Cell 1998; 94: 715–725
   PubMed Web of Science ®Google Scholar
• Guichard S., Montazeri A., Chatelut E., Hennebelle I., Bugat R., Canal P. Schedule-dependent activity of topotecan in OVCAR-3 ovarian carcinoma xenograft: Pharmacokinetic and pharmacodynamic evaluation. Clin Cancer Res 2001; 7: 3222–3228
   PubMed Web of Science ®Google Scholar
• Hu L., Hofmann J., Zaloudek C., Ferrara N., Hamilton T., Jaffe R. B. Vascular endothelial growth factor immunoneutralization plus paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer. Am J Pathol 2002; 161: 1917–1924
   PubMed Web of Science ®Google Scholar
• Hu Y. L., Albanese C., Pestell R. G., Jaffe R. B. Dual mechanisms for lysophosphatidic acid stimulation of human ovarian carcinoma cells. J Natl Cancer Inst 2003; 95: 733–740
   PubMed Web of Science ®Google Scholar
• McCormick D., Chong H., Hobbs C., Datta C., Hall P. A. Detection of the Ki-67 antigen in fixed and wax-embedded sections with the monoclonal antibody MIB1. Histopathology 1993; 22: 355–360
   PubMed Web of Science ®Google Scholar
• Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Vistica D., Warren J. T., Bokesch H., Kenney S., Boyd M. R. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990; 82: 1107–1112
   PubMed Web of Science ®Google Scholar
• Jalava P., Kuopio T., Juntti-Patinen L., Kotkansalo T., Kronqvist P., Collan Y. Ki67 immunohistochemistry: a valuable marker in prognostication but with a risk of misclassification: Proliferation subgroups formed based on Ki67 immunoreactivity and standardized mitotic index. Histopathology 2006; 48: 674–682
   PubMed Web of Science ®Google Scholar
• Goff B. A., Ries J. A., Els L. P., Coltrera M. D., Gown A. M. Immunophenotype of ovarian cancer as predictor of clinical outcome: Evaluation at primary surgery and second-look procedure. Gynecol Oncol 1998; 70: 378–385
   Google Scholar
• Hasumi Y., Mizukami H., Urabe M., Kohno T., Takeuchi K., Kume A., Momoeda M., Yoshikawa H., Tsuruo T., Shibuya M., Taketani Y., Ozawa K. Soluble FLT-1 expression suppresses carcinomatous ascites in nude mice bearing ovarian cancer. Cancer Res 2002; 62: 2019–2023
   PubMed Web of Science ®Google Scholar
• Barbera-Guillem E., Nyhus J. K., Wolford C. C., Friece C. R., Sampsel J. W. Vascular endothelial growth factor secretion by tumor-infiltrating macrophages essentially supports tumor angiogenesis, and IgG immune complexes potentiate the process. Cancer Res 2002; 62: 7042–7049
   PubMed Web of Science ®Google Scholar
• Osusky K. L., Hallahan D. E., Fu A., Ye F., Shyr Y., Geng L. The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels. Angiogenesis 2004; 7: 225–233
   PubMedGoogle Scholar
• Hu L., Hofmann J., Jaffe R. B. Phosphatidylinositol 3-kinase mediates angiogenesis and vascular permeability associated with ovarian carcinoma. Clin Cancer Res 2005; 11: 8208–8212
   PubMed Web of Science ®Google Scholar